NCT06007586 2025-12-04
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
Clinical Trials
95 trialsNCT04908787 2025-09-11
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT04534075 2025-09-08
FIDURA
Sahlgrenska University Hospital
Phase 3 Completed
NCT03534453 2025-07-10
L-MOCA
AstraZeneca
Phase 3 Completed
NCT03863860 2025-07-03
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03353831 2025-04-06
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT02891824 2025-02-11
ATALANTE
ARCAGY/ GINECO GROUP
Phase 3 Completed
NCT04227522 2024-11-15
MAMOC
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed
NCT03635489 2024-10-03
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT03402841 2024-08-21
OPINION
AstraZeneca
Phase 3 Completed
NCT04676334 2024-05-07
CATCH-R
pharmaand GmbH
Phase 3 Completed
NCT03940196 2024-03-29
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
NovoCure Ltd.
Phase 3 Completed
NCT00716976 2023-11-09
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group
Phase 3 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT01968213 2023-06-09
ARIEL3
pharmaand GmbH
Phase 3 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT01847274 2023-06-02
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Tesaro, Inc.
Phase 3 Completed
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT03398655 2023-01-10
OVAL
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3 Completed
NCT02997553 2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3 Completed
NCT03106987 2022-10-07
OReO
AstraZeneca
Phase 3 Completed
NCT02477644 2022-08-02
PAOLA-1
Arcagy Research
Phase 3 Completed
NCT02282020 2022-07-26
SOLO3
AstraZeneca
Phase 3 Completed
NCT01462890 2022-07-20
BOOST
AGO Study Group
Phase 3 Completed
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT03180307 2022-02-04
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 3 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT01837251 2021-07-13
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT00866697 2021-02-16
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novartis
Phase 3 Completed
NCT00262990 2020-12-17
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
Phase 3 Completed
NCT01461850 2020-10-14
SCORPION
Catholic University of the Sacred Heart
Phase 3 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT04237090 2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT00028743 2020-04-02
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00477282 2020-03-12
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT00226915 2020-02-17
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Japanese Gynecologic Oncology Group
Phase 3 Completed
NCT00001806 2019-12-12
Methods in Education for Breast Cancer Genetics
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00262847 2019-07-23
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003644 2019-06-04
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
GOG Foundation
Phase 3 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT00011986 2019-04-16
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Completed
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT00426257 2018-08-24
Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer
The Netherlands Cancer Institute
Phase 3 Completed
NCT02107066 2018-04-20
WALC
Yale University
Phase 3 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT00434642 2017-08-09
OCEANS
Genentech, Inc.
Phase 3 Completed
NCT01684878 2017-05-23
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
Hoffmann-La Roche
Phase 3 Completed